Shows teclistamab plus daratumumab improves progression-free survival in myeloma patients, indicating a promising treatment option.
In patients with multiple myeloma who had received one to three previous lines of therapy, those in the teclistamab-daratumumab group had significantly longer progression-free survival than those in the DPd or DVd group. (Funded by Johnson & Johnson; ClinicalTrials.gov number, NCT05083169.).
No takes yet. Share an insight, caveat, or question.
Costa et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: